GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Obstructive Pulmonary Disease overview

Chronic obstructive pulmonary disease (COPD) is a group of diseases that cause breathing problems and airflow blockage. It includes chronic bronchitis and emphysema. COPD can damage the lungs or clog them with phlegm. Symptoms include cough with or without phlegm, difficulty breathing, wheezing, tiredness. Treatment options include quit smoking, inhalers (short-acting bronchodilator inhalers are the first treatment used.) and tablets, pulmonary rehabilitation.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

G lobalDat a, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.